Fc receptor inside-out signaling and possible impact on antibody therapy

• Published in: Immunological reviews Vol. 268; no. 1; pp. 74 - 87
• Main Authors: Brandsma, Arianne M., Jacobino, Shamir R., Meyer, Saskia, ten Broeke, Toine, Leusen, Jeanette H. W.
• Format: Journal Article
• Language: English
• Published: England Blackwell Publishing Ltd 01.11.2015
• Subjects: Animals; antibodies; Antibodies, Monoclonal - pharmacology; Antibodies, Monoclonal - therapeutic use; Antigens, CD - chemistry; Antigens, CD - genetics; Antigens, CD - metabolism; cytokines; Fc receptors; Humans; Immunoglobulins - immunology; Immunoglobulins - metabolism; Immunomodulation - drug effects; immunotherapy; inside-out signaling; integrins; Integrins - metabolism; Protein Binding; Protein Interaction Domains and Motifs; Receptors, Fc - chemistry; Receptors, Fc - genetics; Receptors, Fc - metabolism; Receptors, IgG - chemistry; Receptors, IgG - genetics; Receptors, IgG - metabolism; Signal Transduction - drug effects; Fc receptors; integrins; antibodies; cytokines; inside-out signaling; immunotherapy
• ISSN: 0105-2896; 1600-065X
• DOI: 10.1111/imr.12332

Summary Fc receptors (FcR) are expressed on immune cells and bind to the Fc tail of antibodies. This interaction is essential for FcR‐mediated signaling and triggering of cellular effector functions. FcR activation is tightly regulated to prevent immune responses by non‐antigen bound antibodies or in the absence of ‘danger signals’. FcR activity may be modulated at the plasma membrane via cross‐talk with integrins. In addition, cytokines at the site of infection/inflammation can increase FcR avidity, a process referred to as inside‐out signaling. This regulatory mechanism has been described for FcγRI (CD64), FcγRIIa (CD32a), and FcαRI (CD89) and is also well‐known for integrins. Key cellular events during inside‐out signaling are (de)phosphorylation, clustering, cytoskeleton rearrangements, and conformational changes. The latter can be studied with antibodies that specifically recognize epitopes exposed by the active (high affinity) or inactive (low affinity) state of the FcR. These antibodies are important tools to investigate the role of FcR activation in disease settings. Research on FcR has gained momentum with the rise of monoclonal antibodies (mAb) entering the clinic for the treatment of cancer and other diseases. The clinical outcome of mAb therapy may be improved by increasing FcR avidity by cytokine stimulation.